Inputs: momentum, trendVelocity
Momentum 0/100 with trend velocity 24/100 — trend is rolling over.
Prediction result · Ensemble engineUpdated 4:36 AM
AGMBAgomAb Therapeutics NV stock price outlook
$7.49-5.79% since prev closeBearish
AgomAb Therapeutics NV (AGMB) is trading at $7.49, down 5.79% since the previous close and -17.24% over the past week. Price sits below its 50-day average by 31.41%, with price momentum at 0/100 and trend velocity at 24/100. Sentiment across 5 recent headlines reads net constructive at 59/100. Volatility risk is elevated (100/100) and the stock is 8% of the way up its 52-week range. The weighted factor score lands at 19/100 — a bearish signal. Research only, not investment advice.
Universal leanmarket
AGMB
AgomAb Therapeutics NV
$7.49-5.79%
LEANSOFT caution / pressure
WHY
- AgomAb Therapeutics NV (AGMB) is trading at $7.49, down 5.79% since the previous close and -17.24% over the past week. Price sits below its 50-day average by 31.41%, with price momentum at 0/100 and trend velocity at 24/100. Sentiment across 5 recent headlines reads net constructive at 59/100. Volatility risk is elevated (100/100) and the stock is 8% of the way up its 52-week range. The weighted factor score lands at 19/100 — a bearish signal. Research only, not investment advice.
- Bear input: Momentum 0/100 with trend velocity 24/100 — trend is rolling over.
RISK
Signals are model output from public data, not personalized investment advice.
INVALIDATE
Invalidate on a reclaim of the session offer, catalyst relief, or model edge flipping bullish.
AI Signal
Bearish · Strong bearish edge
live data
Full public-market mode: chart history, quote, and news inputs were available.
Chart feed
Cron market chart feed
Quote/history
Six-month public chart history loaded.
News feed
5 relevant headlines found.
Signal inputs
Technical factors and news sentiment evaluated across multiple signal inputs.
News Sentiment59/100
Price Momentum0/100
Trend Velocity24/100
Volatility Risk100/100
Historical Modeling: Visualized ranges are mathematically derived from historic volatility metrics, corporate filings, and option-implied volume profiles. They represent statistical points of interest for research purposes, not financial execution commands or advice.
Why It Matters
Signal Explanation
AgomAb Therapeutics NV (AGMB) is trading at $7.49, down 5.79% since the previous close and -17.24% over the past week. Price sits below its 50-day average by 31.41%, with price momentum at 0/100 and trend velocity at 24/100. Sentiment across 5 recent headlines reads net constructive at 59/100. Volatility risk is elevated (100/100) and the stock is 8% of the way up its 52-week range. The weighted factor score lands at 19/100 — a bearish signal. Research only, not investment advice.
Analyst Engine · Specialist model ensemble
50% of trees lean bearish on AGMB
Weighted factor score across 16 signal inputs evaluating 9 features: momentum, news, volume, volatility, range, sentiment divergence, trend structure, and oscillator. Consensus and weighting applied. Each specialist bot inspects a different slice of the feature set, casts a directional vote, and contributes a confidence weight to the final score.
Engine edgeStrong bearish edgeBearish
Inputs: newsSentiment, dayChange
Sentiment 59/100 + price -5.8% are both mid-range.
Inputs: unusualVolume, dayChange
High volume on a down-move — distribution signature.
Inputs: volatilityRisk, momentum
High volatility (100/100) without momentum support — wide path, more downside variance.
Inputs: pctOfRange, trendVelocity
Mid-range positioning — no edge from range alone.
Inputs: newsSentiment, weekChange
Sentiment 59/100 vs week change -17.2% are in agreement — no divergence edge.
Inputs: vsSma50, momentum
Price -31.4% under 50d SMA with no momentum reclaim — downtrend intact.
Inputs: momentum, trendVelocity
Composite oscillator at 12 — washed-out zone, mean-reversion candidate.
Inputs: momentum, dayChange, vsSma50
Momentum 0/100 with negative tape and price under the 50d SMA — downside continuation.
Inputs: newsSentiment, weekChange
News 59/100 and weekly change -17.2% do not create a clean follow-through read.
Inputs: unusualVolume, trendVelocity
Volume 74/100 does not show a dry-up signal.
Inputs: volatilityRisk, pctOfRange, momentum
Very high volatility (100/100) with weak momentum is a rough setup for holders.
Inputs: pctOfRange, dayChange, weekChange
Price is near the bottom of its 52-week range and the tape is still leaking lower.
Inputs: newsSentiment, momentum, weekChange
Sentiment 59/100 and momentum 0/100 are not aligned enough for a clean read.
Inputs: vsSma50, momentum, trendVelocity
Price is still under the 50d SMA and the trend has not reclaimed control.
Inputs: momentum, trendVelocity, weekChange
Oscillator at 12 does not show a rebound edge.
Why the ensemble agrees
- Momentum 0/100 with trend velocity 24/100 — trend is rolling over.
- High volume on a down-move — distribution signature.
- High volatility (100/100) without momentum support — wide path, more downside variance.
Counter-trees
- Composite oscillator at 12 — washed-out zone, mean-reversion candidate.
Bull Case
- Composite oscillator at 12 — washed-out zone, mean-reversion candidate.
Bear Case
- Momentum 0/100 with trend velocity 24/100 — trend is rolling over.
- High volume on a down-move — distribution signature.
- High volatility (100/100) without momentum support — wide path, more downside variance.
Latest Market Headlines
Headline titles only, from the publisher named on each card. Each links to the original story.
Yahoo Finance57
Is AgomAB Therapeutics NV (AGMB) Stock a Biotech Opportunity With Targeted Tissue Therapy Potential?
7/2/2026, 1:06:00 PM
Yahoo Finance60
AgomAb Therapeutics (AGMB) Wins U.S. Patent for AGMB-447
4/12/2026, 11:46:00 AM
The Globe and Mail58
Analysts Are Bullish on Top Healthcare Stocks: Pharvaris (PHVS), AgomAb Therapeutics NV ADR (AGMB)
10/27/2026, 6:32:00 AM
The Globe and Mail63
Agomab Moves Inhaled IPF Drug AGMB-447 Into Phase 2 After Positive Phase 1 Results
9/15/2026, 1:54:00 PM
Nasdaq56
Agomab Announces Positive Phase 1 Results for AGMB-447 in Patients with Idiopathic Pulmonary Fibrosis and Design of Phase 2 INSPIRIA Study
9/14/2026, 1:05:00 PM
Key stats
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Market cap
- $368.9M
- 52-week range
- $17.82/$7.45
- Volume
- 197,838
- Avg volume
- 153,929
- Analyst 1-yr target
- $34.50
- Exchange
- NASDAQ-GS
Source: Nasdaq public quote data. Research only.
Insider trades
2 buys · 0 sells by AGMB insiders (SEC Form 4 filings)
- BUY Epstein David R Director · 2026-10-22$45K
- BUY Epstein David R Director · 2026-10-22$44K
Earnings Intelligence
Next
N/A
Estimate
N/A
Actual
N/A
- • Earnings data is not available from the public feed used on this page.
- • Price, news, and model inputs are live.
- • Use an exchange or broker calendar for the official earnings schedule.
Risk Warnings
- • Signals are model output from public data, not personalized investment advice.
- • High volatility — position sizing and stops matter more here.
- • Confirm liquidity, spreads, and your own thesis before acting.
AGMB questions
What is the MarketPicks AI signal for AgomAb Therapeutics NV stock (AGMB)?
As of Nov 1, 11:36 PM ET, the ensemble reads bearish on AGMB — bearish — 8 of 16 bots down, with 1 bull, 8 bear and 7 hold votes from 16 specialist bots. Research only, not investment advice.
What is the latest AGMB price on MarketPicks?
AGMB was $7.49 on the latest quote (Nov 1, 11:36 PM ET), -5.79% since the previous close. Quotes can be delayed.
What do the momentum and trend scores for AGMB mean?
Scores run from 0 to 100, with 50 neutral. AGMB shows momentum 0/100, trend velocity 24/100 and volatility risk 100/100, with news sentiment at 59/100.
Not financial advice. MarketPicks.ai is an impersonal research tool. AI output can be wrong. Investing involves risk of loss. Do your own research and consult a licensed professional. Full disclaimer.